/ Natco Pharma Receives US FDA Nod For Generic Bendamustine HCL Powde, Stocks Up 5% ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Friday, 6 January 2017

Natco Pharma, a leading manufacturer of finished dosage formulations (FDFs) and active pharmaceutical ingredients (APIs) recently has received final US FDA nod for its generic version of Bendamustine Hydrochloride powder used in injections, 25mg/Vial and 100 mg/vial. Going forward the company has plans to launch Bendamustine in US on November 1, 2019 or earlier if possible.

The company would launch the same through Breckenridge, its marketing partner in the US market.
Currently, Cephalon powered by Teva, markets this Bendamustine Hydrochloride powder under the name Treanda in the US market.

The dosage treats patients with chronic lymphocytic leukemia  (CLL) and  non-hodgkin’s lymphoma.
The stock of Natco Pharma has outperformed the entire Pharma sector and has surged as much as 5.6%, standing at Rs 630.8. It has just broken out of its 50 and 100 days EMA levels. The stock will confirm its consolidation breakout if it sustains above the mentioned levels on a closing basis.
For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717